No Data
JonesTrading Maintains Janux Therapeutics(JANX.US) With Buy Rating, Maintains Target Price $70
Have Insiders Sold Janux Therapeutics Shares Recently?
Form 144 | Janux Therapeutics(JANX.US) 10% Stockholder Proposes to Sell 9.22 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Oct 25, $Janux Therapeutics(JANX.US)$ 10% Stockholder Avalon BioVentures SPV I, L.P. intends to sell 172.88K shares of its common stock on Oct 25, with a total market value
UBS Launches SMID Cap Biotechs With Cancer, Autoimmunity in Focus
Cracking The Code: Understanding Analyst Reviews For Janux Therapeutics
UBS Initiates Janux Therapeutics(JANX.US) With Buy Rating, Announces Target Price $69
No Data
No Data
